Structures by: Gonnade R. G.
Total: 375
C13H11IN2S
C13H11IN2S
CrystEngComm (2016) 18, 37 7078
a=12.6626(17)Å b=7.0591(10)Å c=15.395(2)Å
α=90° β=94.006(2)° γ=90°
C13H10FIN2O
C13H10FIN2O
CrystEngComm (2016) 18, 37 7078
a=27.607(6)Å b=4.6224(11)Å c=9.750(2)Å
α=90° β=93.235(3)° γ=90°
C14H13IN2OS
C14H13IN2OS
CrystEngComm (2016) 18, 37 7078
a=12.481(2)Å b=9.9446(16)Å c=23.867(4)Å
α=90° β=96.736(2)° γ=90°
C13H10IN3O2S
C13H10IN3O2S
CrystEngComm (2016) 18, 37 7078
a=14.2167(19)Å b=14.5308(18)Å c=6.8955(10)Å
α=90.00° β=90.00° γ=90.00°
C13H11IN2S
C13H11IN2S
CrystEngComm (2016) 18, 37 7078
a=15.3895(12)Å b=5.4985(5)Å c=17.1612(15)Å
α=90° β=116.180(4)° γ=90°
C13H11IN2O
C13H11IN2O
CrystEngComm (2016) 18, 37 7078
a=26.1800(17)Å b=4.6273(3)Å c=9.9779(7)Å
α=90.00° β=91.646(3)° γ=90.00°
C13H11IN2O
C13H11IN2O
CrystEngComm (2016) 18, 37 7078
a=27.253(5)Å b=4.6408(9)Å c=9.8532(18)Å
α=90° β=91.991(6)° γ=90°
C17H26N4O6S2
C17H26N4O6S2
Organic & biomolecular chemistry (2015) 13, 10 3064-3069
a=7.7425(4)Å b=10.0108(6)Å c=13.8284(8)Å
α=90.00° β=102.033(3)° γ=90.00°
Peptide
C23H32N4O5
Organic & biomolecular chemistry (2013) 11, 48 8348-8356
a=8.9732(8)Å b=10.4292(9)Å c=25.653(2)Å
α=90.00° β=90.00° γ=90.00°
C18H24N2O5
C18H24N2O5
Organic & biomolecular chemistry (2013) 11, 48 8348-8356
a=8.547(5)Å b=9.694(5)Å c=22.943(12)Å
α=90.00° β=90.00° γ=90.00°
Peptide
C24H28N2O5
Organic & biomolecular chemistry (2013) 11, 48 8348-8356
a=10.6231(7)Å b=10.9569(7)Å c=19.5280(12)Å
α=90.00° β=90.00° γ=90.00°
C12H18O5
C12H18O5
Chem. Commun. (2017)
a=6.2841(15)Å b=10.607(4)Å c=18.103(4)Å
α=98.128(6)° β=97.616(5)° γ=96.180(10)°
C19H22O3
C19H22O3
Chem. Commun. (2017)
a=6.4777(2)Å b=8.9647(2)Å c=13.3928(3)Å
α=93.6160(10)° β=92.6120(10)° γ=93.620(2)°
C14H9F4NO
C14H9F4NO
New J. Chem. (2016) 40, 6 4981
a=8.02180(10)Å b=39.7347(6)Å c=7.88660(10)Å
α=90° β=103.9420(10)° γ=90°
C14H9F4NO
C14H9F4NO
New J. Chem. (2016) 40, 6 4981
a=7.156(3)Å b=7.072(3)Å c=23.277(9)Å
α=90° β=91.651(6)° γ=90°
C14H9F4NO
C14H9F4NO
New J. Chem. (2016) 40, 6 4981
a=12.9475(16)Å b=9.5928(11)Å c=10.0791(12)Å
α=90° β=106.428(7)° γ=90°
C14H9F4NO
C14H9F4NO
New J. Chem. (2016) 40, 6 4981
a=26.9156(8)Å b=9.6838(3)Å c=9.6832(3)Å
α=90° β=90° γ=90°
C14H9BrN4O2
C14H9BrN4O2
CrystEngComm (2009) 11, 1 143
a=9.6141(15)Å b=12.0915(19)Å c=12.900(2)Å
α=87.535(2)° β=71.407(2)° γ=76.183(2)°
? 4-(4-Chlorophenyl)-1-(2-nitrophenyl)-1H-1,2,3-triazole
C14H9ClN4O2
CrystEngComm (2013) 15, 26 5283
a=10.8467(15)Å b=14.129(2)Å c=26.790(4)Å
α=90.00° β=90.00° γ=90.00°
? 4-(4-Chlorophenyl)-1-(2-nitrophenyl)-1H-1,2,3-triazole
C14H9ClN4O2
CrystEngComm (2013) 15, 26 5283
a=7.013(4)Å b=7.312(4)Å c=13.309(7)Å
α=94.793(8)° β=96.114(8)° γ=107.261(8)°
C14H9IN4O2
C14H9IN4O2
CrystEngComm (2013) 15, 26 5283
a=5.4744(14)Å b=11.366(3)Å c=11.235(3)Å
α=90.00° β=93.816(4)° γ=90.00°
C14H9IN4O2
C14H9IN4O2
CrystEngComm (2013) 15, 26 5283
a=7.587(4)Å b=8.310(4)Å c=12.755(6)Å
α=95.053(7)° β=100.946(7)° γ=116.761(7)°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate
C21H16Br2O8
CrystEngComm (2008) 10, 3 288
a=6.8481(14)Å b=11.662(2)Å c=13.675(3)Å
α=107.123(4)° β=99.175(4)° γ=90.909(3)°
Piv-L-tert-Leu-L-Pro-SAnt-NH-IBu
C26H42N4O5S
RSC Adv. (2016)
a=11.0729(4)Å b=11.2306(4)Å c=23.8209(9)Å
α=90° β=90° γ=90°
C14H13IN2OS
C14H13IN2OS
CrystEngComm (2016) 18, 37 7078
a=8.1518(6)Å b=18.2688(13)Å c=9.5334(7)Å
α=90° β=93.6720(10)° γ=90°
C24H24O5
C24H24O5
RSC Adv. (2015)
a=7.9447(10)Å b=19.588(2)Å c=12.7483(14)Å
α=90.00° β=97.927(5)° γ=90.00°
C21H21N3O3
C21H21N3O3
RSC Adv. (2015)
a=13.9952(17)Å b=9.1123(12)Å c=15.2436(19)Å
α=90.00° β=97.909(9)° γ=90.00°
C22H19N5O
C22H19N5O
RSC Adv. (2015)
a=12.3799(12)Å b=13.0555(12)Å c=11.5532(11)Å
α=90.00° β=98.570(5)° γ=90.00°
C17H21CuN3O3,0.5(H2O)
C17H21CuN3O3,0.5(H2O)
Dalton transactions (Cambridge, England : 2003) (2018) 47, 46 16747-16754
a=11.7397(4)Å b=13.8992(5)Å c=21.0927(8)Å
α=90° β=90.547(2)° γ=90°
C34H42Cu2N6O6
C34H42Cu2N6O6
Dalton transactions (Cambridge, England : 2003) (2018) 47, 46 16747-16754
a=13.750(3)Å b=7.8669(17)Å c=16.223(4)Å
α=90° β=98.271(10)° γ=90°
C15H18BrCuN3O
C15H18BrCuN3O
Dalton transactions (Cambridge, England : 2003) (2018) 47, 46 16747-16754
a=14.8335(5)Å b=13.3212(4)Å c=16.1662(5)Å
α=90° β=101.8220(10)° γ=90°
C46H42Cl10F6Ge2N2O6P2S2
C46H42Cl10F6Ge2N2O6P2S2
Dalton transactions (Cambridge, England : 2003) (2019) 48, 21 7344-7351
a=11.0330(10)Å b=12.4374(11)Å c=13.1345(12)Å
α=62.303(3)° β=71.710(3)° γ=64.929(3)°
C42H38Cl2F6Ge2N2O6P2S2
C42H38Cl2F6Ge2N2O6P2S2
Dalton transactions (Cambridge, England : 2003) (2019) 48, 21 7344-7351
a=12.9761(12)Å b=13.6739(14)Å c=13.7965(12)Å
α=85.400(6)° β=86.134(6)° γ=70.497(6)°
C42H38Cl9F3Ga2N2O3P2S
C42H38Cl9F3Ga2N2O3P2S
Dalton transactions (Cambridge, England : 2003) (2019) 48, 21 7344-7351
a=10.8764(4)Å b=37.6034(12)Å c=12.6639(4)Å
α=90° β=104.849(2)° γ=90°
C43H37F9N2O9P2S3
C43H37F9N2O9P2S3
Dalton transactions (Cambridge, England : 2003) (2019) 48, 21 7344-7351
a=14.1906(5)Å b=19.4217(7)Å c=16.8932(6)Å
α=90° β=101.035(2)° γ=90°
1
C25H49I2N3O1Si3Zn,0.5(C4H8O2)
Dalton Trans. (2017)
a=9.825(2)Å b=9.851(2)Å c=19.935(5)Å
α=88.975(4)° β=86.600(4)° γ=70.447(4)°
C42H82I4N6Si6Zn2
C42H82I4N6Si6Zn2
Dalton Trans. (2017)
a=11.0979(4)Å b=15.3333(6)Å c=17.7409(7)Å
α=90° β=91.1100(10)° γ=90°
Tri-O-p-bromo-benzoyl-myo-inositol 1,3,5-orthoformate
C28H19Br3O9
Chemical Communications (2005)
a=57.945(13)Å b=6.0511(13)Å c=15.465(3)Å
α=90.00° β=103.469(4)° γ=90.00°
Tri-O-p-bromo-benzoyl-myo-inositol 1,3,5-orthoformate
C28H19Br3O9
Chemical Communications (2005)
a=10.002(2)Å b=12.126(2)Å c=13.146(3)Å
α=70.536(3)° β=80.100(3)° γ=68.503(3)°
Tri-O-p-chloro-benzoyl-myo-inositol 1,3,5-orthoformate
C28H19Cl3O9
Chemical Communications (2005)
a=10.2740(17)Å b=11.2899(18)Å c=12.717(2)Å
α=75.582(3)° β=86.976(3)° γ=68.503(3)°
4,6-Bis-methylcabamoyl-2,2,8,8-Tetramethyl carbamoyl- nonanedioic acid bis-methylamide
C19H36N4O4
Chemical Communications (2006) 26
a=9.676(3)Å b=12.826(4)Å c=17.434(6)Å
α=90.00° β=90.00° γ=90.00°
4,6-Bis-methylcarbamonyl-nonanedioic acid bis-methylamide
C15H28N4O4
Chemical Communications (2006) 26
a=4.8971(8)Å b=7.7453(13)Å c=23.813(4)Å
α=85.109(3)° β=88.701(3)° γ=76.425(3)°
C15H12O3
C15H12O3
Chemical communications (Cambridge, England) (2008) 27 3151-3153
a=19.374(18)Å b=5.222(5)Å c=24.39(2)Å
α=90.00° β=109.910(15)° γ=90.00°
C16H14O4
C16H14O4
Chemical communications (Cambridge, England) (2008) 27 3151-3153
a=7.896(2)Å b=12.117(3)Å c=13.238(4)Å
α=90.00° β=97.439(5)° γ=90.00°
C22H24N4O4
C22H24N4O4
Chem.Commun. (2012) 48, 11205
a=10.4632(17)Å b=11.4185(19)Å c=16.753(3)Å
α=90.00° β=90.00° γ=90.00°
C22H24N4O4
C22H24N4O4
Chem.Commun. (2012) 48, 11205
a=10.4654(8)Å b=11.4224(9)Å c=16.7268(13)Å
α=90.00° β=90.00° γ=90.00°
C20H20N4O5
C20H20N4O5
Chem.Commun. (2012) 48, 11205
a=10.9252(7)Å b=8.9395(6)Å c=11.2908(7)Å
α=90.00° β=116.821(2)° γ=90.00°
C23H26N4O5
C23H26N4O5
Chem.Commun. (2012) 48, 11205
a=7.564(3)Å b=15.725(7)Å c=18.913(8)Å
α=90.00° β=90.00° γ=90.00°
C31H27BrN4O5
C31H27BrN4O5
Chem.Commun. (2012) 48, 11205
a=9.628(3)Å b=11.943(4)Å c=12.282(4)Å
α=90.00° β=91.847(6)° γ=90.00°
C20H21N3O3
C20H21N3O3
Chem.Commun. (2012) 48, 11205
a=21.610(3)Å b=8.6706(12)Å c=21.210(3)Å
α=90.00° β=118.719(2)° γ=90.00°
C16H24O8
C16H24O8
Chem.Commun. (2012) 48, 717
a=19.6432(17)Å b=10.0493(8)Å c=9.1485(8)Å
α=90.00° β=98.896(8)° γ=90.00°
C22H36O8
C22H36O8
Chem.Commun. (2012) 48, 717
a=6.2347(3)Å b=9.7994(5)Å c=21.2685(12)Å
α=90.067(4)° β=96.665(4)° γ=96.717(4)°
C26H28O8
C26H28O8
Chem.Commun. (2012) 48, 717
a=11.5979(10)Å b=12.7445(11)Å c=18.9854(16)Å
α=88.4850(10)° β=75.2590(10)° γ=68.6780(10)°
C19H24O7
C19H24O7
Chem.Commun. (2012) 48, 717
a=20.438(2)Å b=8.4112(9)Å c=10.6083(11)Å
α=90.00° β=104.937(2)° γ=90.00°
C23H26O7
C23H26O7
Chem.Commun. (2012) 48, 717
a=12.8719(17)Å b=9.8278(13)Å c=32.197(4)Å
α=90.00° β=90.00° γ=90.00°
C29H28O7
C29H28O7
Chem.Commun. (2012) 48, 717
a=18.7371(18)Å b=7.1054(7)Å c=18.9941(18)Å
α=90.00° β=108.8720(10)° γ=90.00°
Iressa
C22H24ClFN4O3
CrystEngComm (2014) 16, 37 8638
a=7.1645(2)Å b=10.8025(3)Å c=14.3429(4)Å
α=80.3020(10)° β=75.6620(10)° γ=89.2670(10)°
Iressa
C22H24ClFN4O3
CrystEngComm (2014) 16, 37 8638
a=8.8091(4)Å b=9.6702(4)Å c=12.4941(5)Å
α=93.700(2)° β=97.546(2)° γ=101.939(2)°
C34H45O11
C34H45O11
RSC Advances (2014) 4, 53 27661
a=10.6696(13)Å b=13.6752(17)Å c=11.3635(14)Å
α=90.00° β=102.968(6)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate dimethyl sulphoxide solvate
C21H16Cl2O8,C2H6OS
CrystEngComm (2010) 12, 12 4184
a=12.9731(13)Å b=10.2342(11)Å c=18.0469(19)Å
α=90.00° β=102.585(2)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate dioxane solvate
C21H16Cl2O8,C4H8O2
CrystEngComm (2010) 12, 12 4184
a=13.047(3)Å b=10.141(3)Å c=18.678(5)Å
α=90.00° β=103.518(4)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate 1,2- dichloroethane solvate
C21H16Cl2O8,C2H4Cl2
CrystEngComm (2010) 12, 12 4184
a=12.093(2)Å b=9.9108(17)Å c=20.260(3)Å
α=90.00° β=92.433(3)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate acetonitrile solvate
C21H16Cl2O8,C2H3N
CrystEngComm (2010) 12, 12 4184
a=12.074(10)Å b=9.861(8)Å c=20.003(16)Å
α=90.00° β=94.894(13)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate benzene solvate
C21H16Cl2O8,0.5(C6H6)2
CrystEngComm (2010) 12, 12 4184
a=32.22(3)Å b=9.584(8)Å c=21.386(19)Å
α=90.00° β=129.72(3)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate dichloromethane solvate
C21H16Cl2O8,0.06(CH2Cl2)
CrystEngComm (2010) 12, 12 4184
a=12.962(2)Å b=10.1406(17)Å c=18.391(3)Å
α=90.00° β=102.627(3)° γ=90.00°
Hexa-O-toluoyl-myo-inositol
C54H48O12
CrystEngComm (2010) 12, 2 478
a=12.150(8)Å b=14.363(7)Å c=16.451(11)Å
α=99.374(15)° β=106.419(12)° γ=111.167(14)°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate chloroform solvate
C21H16Br2O8,CHCl3
CrystEngComm (2010) 12, 12 4184
a=12.8141(17)Å b=10.2601(14)Å c=18.756(3)Å
α=90.00° β=102.832(2)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate acetone solvate
C21H16Br2O8,C3H6O
CrystEngComm (2010) 12, 12 4184
a=12.8133(15)Å b=10.2045(12)Å c=18.814(2)Å
α=90.00° β=103.599(2)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate dichloromethane solvate
C21H16Br2O8,CH2Cl2
CrystEngComm (2010) 12, 12 4184
a=12.8524(11)Å b=10.2018(8)Å c=18.5250(15)Å
α=90.00° β=102.8700(10)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate nitromethane solvate
C21H16Br2O8,CH3NO2
CrystEngComm (2010) 12, 12 4184
a=12.1747(15)Å b=10.1533(12)Å c=19.261(2)Å
α=90.00° β=103.231(2)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate tetrahydrofuran solvate
C21H16Br2O8,C4H8O
CrystEngComm (2010) 12, 12 4184
a=13.181(4)Å b=10.046(3)Å c=18.813(5)Å
α=90.00° β=102.436(4)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate dioxane solvate
C21H16Br2O8,C4H8O2
CrystEngComm (2010) 12, 12 4184
a=13.1856(16)Å b=10.2483(13)Å c=18.966(2)Å
α=90.00° β=104.704(2)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate dimethyl sulphoxide solvate
C21H16Br2O8,C2H6OS
CrystEngComm (2010) 12, 12 4184
a=13.0322(15)Å b=10.2499(11)Å c=18.415(2)Å
α=90.00° β=103.579(2)° γ=90.00°
2,6-di-O-p-bromobenzoyl-myo-inositol 1,3,5-orthoformate 1,2- dichloroethane solvate
C21H16Br2O8,C2H4Cl2
CrystEngComm (2010) 12, 12 4184
a=12.1687(8)Å b=10.0099(7)Å c=20.3518(14)Å
α=90.00° β=92.6770(10)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate chloroform solvate
C21H16Cl2O8,CHCl3
CrystEngComm (2010) 12, 12 4184
a=12.9486(9)Å b=10.2705(7)Å c=18.0529(12)Å
α=90.00° β=101.3980(10)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate acetone solvate
C21H16Cl2O8,C3H6O
CrystEngComm (2010) 12, 12 4184
a=12.751(2)Å b=10.2210(18)Å c=18.520(3)Å
α=90.00° β=103.209(3)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate dichloromethane solvate
C21H16Cl2O8,CH2Cl2
CrystEngComm (2010) 12, 12 4184
a=12.8921(11)Å b=10.1356(9)Å c=18.0788(16)Å
α=90.00° β=101.5840(10)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate nitromethane solvate
C21H16Cl2O8,CH3NO2
CrystEngComm (2010) 12, 12 4184
a=12.6835(7)Å b=10.0712(5)Å c=18.2980(10)Å
α=90.00° β=103.1000(10)° γ=90.00°
2,6-di-O-p-chlorobenzoyl-myo-inositol 1,3,5-orthoformate tetrahydrofuran solvate
C21H16Cl2O8,C4H8O
CrystEngComm (2010) 12, 12 4184
a=12.908(3)Å b=10.135(2)Å c=18.299(4)Å
α=90.00° β=101.682(4)° γ=90.00°
C19H33ClNOPPd
C19H33ClNOPPd
Dalton transactions (Cambridge, England : 2003) (2014) 43, 42 16084-16096
a=8.2182(2)Å b=12.9877(3)Å c=20.2391(5)Å
α=90.00° β=90.00° γ=90.00°
C21H37ClNOPPd
C21H37ClNOPPd
Dalton transactions (Cambridge, England : 2003) (2014) 43, 42 16084-16096
a=13.4029(16)Å b=8.1183(10)Å c=21.221(3)Å
α=90.00° β=103.850(8)° γ=90.00°
3'-Fluoro-3'-deoxy-5-methyluridine
C10H13FN2O5
Acta Crystallographica Section C (2020) 76, 4
a=7.0301(3)Å b=17.1705(8)Å c=18.8369(9)Å
α=90° β=90° γ=90°
4-<i>O</i>-Benzoyl-2-<i>O</i>-phenoxythiocarbonyl-<i>myo</i>-inositol 1,3,5-orthoformate
C21H18O8S
Acta Crystallographica Section C (2016) 72, 11 875-881
a=14.5888(7)Å b=6.0440(3)Å c=21.5364(12)Å
α=90° β=100.216(2)° γ=90°
Pyrazinamide--<i>p</i>-aminobenzoic acid (1/1)
C7H7N1O2,C5H5N3O1
Acta Crystallographica Section C (2015) 71, 11
a=7.9293(8)Å b=15.1231(16)Å c=10.2490(12)Å
α=90.00° β=100.862(6)° γ=90.00°
4-(Pyrazine-2-carboxamido)benzoic acid
C12H9N3O3
Acta Crystallographica Section C (2015) 71, 11
a=6.0535(5)Å b=7.4159(6)Å c=13.2548(10)Å
α=85.612(5)° β=81.900(5)° γ=66.398(5)°
C15H18N2O4
C15H18N2O4
Acta Crystallographica Section B (2020) 76, 5
a=12.7410(4)Å b=7.7542(3)Å c=29.3961(11)Å
α=90° β=98.6000(10)° γ=90°
C15H18N2O4
C15H18N2O4
Acta Crystallographica Section B (2020) 76, 5
a=7.3324(9)Å b=29.277(3)Å c=7.4171(8)Å
α=90° β=117.402(4)° γ=90°
C15H18N2O4
C15H18N2O4
Acta Crystallographica Section B (2020) 76, 5
a=7.1190(2)Å b=7.2678(3)Å c=15.0171(6)Å
α=78.0120(10)° β=82.1820(10)° γ=66.0070(10)°
C15H18N2O4
C15H18N2O4
Acta Crystallographica Section B (2020) 76, 5
a=7.3901(5)Å b=25.1748(18)Å c=8.0438(6)Å
α=90° β=108.992(3)° γ=90°
C15H18N2O4
C15H18N2O4
Acta Crystallographica Section B (2020) 76, 5
a=13.1277(19)Å b=13.977(2)Å c=17.802(3)Å
α=80.629(5)° β=82.485(5)° γ=62.419(5)°
Metronidazole
C6H9N3O3
Acta Crystallographica Section B (2019) 75, 6
a=6.87850(10)Å b=8.63960(10)Å c=12.8573(2)Å
α=90° β=94.3510(10)° γ=90°
Gefitinib--azelaic acid (1/1)
C22H24ClFN4O3,C9H16O4
Acta Crystallographica Section E (2020) 76, 6 884-888
a=10.7716(10)Å b=7.4153(13)Å c=38.175(7)Å
α=90° β=92.311(5)° γ=90°
Di-<i>tert</i>-butyl N,N'-(octahydropentalene-2,5-diyl)dicarbamate
C18H32N2O4
Acta Crystallographica Section E (2008) 64, 6 o1149
a=33.161(17)Å b=6.060(3)Å c=9.926(5)Å
α=90.00° β=95.594(9)° γ=90.00°
6,6-Dibenzyltetrazolo[1,5-<i>a</i>]pyrimidine-5,7(4<i>H</i>,6<i>H</i>)-dione
C18H15N5O2
Acta Crystallographica Section E (2007) 63, 8 o3550-o3550
a=8.6247(13)Å b=16.777(3)Å c=22.950(4)Å
α=90.00° β=90.00° γ=90.00°
Myo inositol
C21H18O8
Acta Crystallographica Section C (2014) 70, 11 1040-1045
a=16.6753(7)Å b=9.8281(5)Å c=22.4931(10)Å
α=90.00° β=90.747(2)° γ=90.00°
Myo inositol cocrystal
C21H18O8,C10H8N2
Acta Crystallographica Section C (2014) 70, 11 1040-1045
a=10.7434(3)Å b=11.4077(4)Å c=11.7341(4)Å
α=82.246(2)° β=65.849(2)° γ=89.549(2)°
4,6-di-O-benzyl-myo-inositol 1,3,5-orthoformate
C21H22O6
Acta Crystallographica Section C (2005) 61, 11 o628-o630
a=9.0511(11)Å b=10.0953(12)Å c=10.6586(13)Å
α=68.849(2)° β=81.453(2)° γ=87.433(2)°
4,6-di-<i>O</i>-acetyl-2-<i>O</i>-tosyl-<i>myo</i>-inositol 1,3,5-orthoformate
C18H20O10S
Acta Crystallographica Section C (2009) 65, 7 o335-o338
a=8.5756(6)Å b=11.0381(8)Å c=11.2005(8)Å
α=100.4260(10)° β=103.1230(10)° γ=99.6600(10)°
4,6-di-<i>O</i>-acetyl-2-<i>O</i>-tosyl-<i>myo</i>-inositol 1,3,5-orthobenzoate
C24H24O10S
Acta Crystallographica Section C (2009) 65, 7 o335-o338
a=12.3019(14)Å b=8.2155(10)Å c=23.551(3)Å
α=90.00° β=91.306(2)° γ=90.00°